It can be seen from analysis on major blood grouping analyzer-related patent applications published in the 3 years from 2018 to 2021 that benefited from the basically stable original technologies of the industry; domestic enterprises have continuously increased R&D inputs, constantly improved technical innovation capability, made breakthroughs in many technologies, and developed a batch of core components of instruments with independent intellectual property rights through follow-on R&D strategy.

China plans to accelerate the establishment of a tiered healthcare delivery system, focusing on strengthening primary-level medical capacity to manage common and chronic diseases such as hypertension and diabetes, authorities said.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026.

Group sales were +6% at constant exchange rates (CER), -5% when reported in CHF and +9% in USD, in the first three months, driven by high demand for our innovative medicines and diagnostics.

Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, announced today that it was granted CE marking under the European Union In Vitro Diagnostic Regulation (EU IVDR) for both its ArteraAI Prostate Biopsy Assay and ArteraAI Breast Cancer Assay, marking a major step in the company’s global expansion.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enhance Merck’s digital backbone as an AI-enabled enterprise. This multi-year investment, valued at up to $1 billion, will deploy an agentic platform across Merck’s research & development (R&D), manufacturing, commercial, and corporate functions – and includes Google Cloud engineers working alongside Merck teams to deploy Google Cloud’s most sophisticated AI, including Gemini Enterprise.

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.

Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

Boehringer Ingelheim has launched a new artificial intelligence (AI) and machine learning (ML) centre in London, representing the company’s latest move to drive improved patient outcomes through the technologies’ application.

QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and CLIA waiver in February 2026.

QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenue for the first quarter of 2026, ended March 29, 2026, and provided an update on its full-year 2026 financial guidance. The Company also announced its plan to release its full first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes.

Siemens (SIEGn.DE), opens new tab said on Friday it planned a shareholder vote on a ​direct spin-off of Siemens Healthineers (SHLG.DE), opens new tab shares ‌at its next shareholder meeting in February 2027.